Human Anti-Tetanus Toxoid ELISA Kit

Tetanus is a non-infectious neurological disease caused by the potent exotoxin tetanus toxin (TeNT) produced by Clostridium tetani. C. tetani is an anaerobic spore-forming bacterium commonly found in warm, moist soil. Its spores can enter animal bodies through open wounds, germinating in anaerobic conditions after a latent period of 3-21 days. Tetanus toxin is synthesized and released within necrotic tissue, where it binds to presynaptic membranes of motor and sensory neurons. It travels retrogradely along axons into the central nervous system, blocking neurotransmitter release, and causing symptoms such as muscle spasms, paralysis, and "lockjaw." Without treatment, tetanus has a 100% mortality rate due to the toxin's lethal levels that prevent immune response. Records of tetanus-like symptoms date back to around 3000 BC, claiming countless lives until TeNT was isolated in 1890 as the primary culprit.

Figure 1. Ribbon Diagram of Structural Domains of Tetanus Toxin (Source: Lockyer K, et al., 2015)

Vaccination with tetanus toxoid, based on TeNT, induces antibodies against the toxin, effectively preventing tetanus. Tetanus toxoid is TeNT that has been chemically inactivated. Industrially, clinical strains of C. tetani are fermented in complex media to produce TeNT, which is then formalin-inactivated to obtain tetanus toxoid. Unlike TeNT, tetanus toxoid lacks toxicity but retains immunogenicity. Despite the industrial manufacture of tetanus vaccinations, tetanus remains a major public health concern, particularly in countries with limited resources and underserved areas where vaccination coverage among the elderly, pregnant women, and infants is low and information on relevant factors is scarce. In this setting, establishing effective tetanus therapies and doing additional research suited to certain demographics and regions is critical.

Clinically, tetanus toxoid is not only used in tetanus vaccine production but also in evaluating vaccine efficacy and safety, co-formulating conjugate vaccines with other antigens, studying immune response mechanisms as a model antigen, investigating tetanus toxin action mechanisms, and potentially developing therapies for certain neurological or autoimmune diseases. Notably, tetanus toxoid conjugated with other antigens (typically polysaccharides) in vaccines like pneumococcal conjugate vaccine, Hib vaccine, meningococcal conjugate vaccine, etc., significantly enhances vaccine efficacy, especially in children.

Human Anti-Tetanus Toxin ELISA Kit
Human Anti-Tetanus Toxoid Assay Kit
Anti-Tetanus Toxoid ELISA Kit